Class action lawsuits
Securities class action lawsuit filed against Sarepta Therapeutics, Inc. alleging false and misleading statements regarding the safety and efficacy of its prescription gene therapy, ELEVIDYS. The lawsuit claims that investors suffered damages when the true details of the therapy's risks entered the market. Investors who purchased Sarepta securities
Class action lawsuits
Investors who purchased or acquired Sarepta Therapeutics, Inc. (NASDAQ: SRPT) securities between June 22, 2023, and June 24, 2025, may be eligible to participate in a class action lawsuit. The suit alleges that Sarepta misled investors regarding the safety of its ELEVIDYS drug, which is intended to treat Duchenne muscular
Class action lawsuits
A shareholder has filed a securities class action lawsuit on behalf of investors who purchased or acquired Centene Corporation securities between December 12, 2024 and June 30, 2025. The lawsuit alleges that the Defendants made misrepresentations concerning Centene's enrollment and morbidity rates. This lawsuit may provide an opportunity
Class action lawsuits
Investors are suing Centene Corporation, a leading healthcare provider, after the company allegedly misstated its financial guidance, hiding the fact that the majority of its market was experiencing lower than expected enrollment growth and increased morbidity rates. The lawsuit seeks to recover losses for investors who purchased Centene securities between
Class action lawsuits
Pomerantz LLP is conducting an investigation into potential securities law violations by Neogen Corporation, following the company's disclosure of disappointing fourth-quarter financial results. On June 4, 2025, Neogen announced an expected EBITDA margin decline due to elevated inventory write-offs, which caused its stock price to plummet by 17.
Class action lawsuits
A class action lawsuit has been filed against Neogen Corporation (NASDAQ: NEOG) and certain of its officers by Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm that specializes in securities fraud class actions. The lawsuit alleges that the company and its officers made false and misleading statements about
Class action lawsuits
Altimmune, Inc.'s securities fraud allegations have sparked a class action lawsuit, seeking to recover losses for shareholders affected by the company's supposed misleading statements. The lawsuit claims that Altimmune intentionally deceived investors by showcasing inflated expectations for its Pemvidutide treatment in the IMPACT Phase 2b MASH
Class action lawsuits
Reddit's stock price plummeted after investors were misled about the site's traffic and user engagement. The lawsuit claims that between October 29, 2024, and May 20, 2025, Reddit's leadership made false statements to investors about the impact of changes to Google Search's
Class action lawsuits
Investors who purchased the Western Asset US Core Bond Fund mutual fund classes between January 1, 2021, and October 31, 2023, may be entitled to compensation without payment of out-of-pocket fees or costs. The Rosen Law Firm, a global investor rights law firm, reminds investors of the important September 5,
Class action lawsuits
A lawsuit has been filed against Centene Corporation, a leading healthcare company, and its senior executives for potential violations of federal securities laws. The lawsuit was filed by a securities law firm on behalf of investors who purchased Centene securities. The complaint alleges that the company made false statements about
Class action lawsuits
XPLR Infrastructure, LP, formerly known as Nextera Energy Partners, LP, has been embroiled in controversy with the filing of a class action lawsuit by the Rosen Law Firm, a global investor rights law firm, on behalf of common unit holders between September 27, 2023, and January 27, 2025. The lawsuit
Class action lawsuits
Pomerantz LLP has announced that a class action lawsuit has been filed against Hims & Hers Health, Inc. (NYSE: HIMS) on allegations of securities fraud and other unlawful business practices. The lawsuit concerns the company's promotion and sale of compounded drugs under the guise of "personalization."
